Your session is about to expire
← Back to Search
Exemestane for Non-Small Cell Lung Cancer
Phase 2
Waitlist Available
Led By Manish Patel, DO
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year after enrollment
Awards & highlights
Study Summary
This study is evaluating whether adding an additional drug to immune checkpoint therapy may help treat lung cancer.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year after enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year after enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Disease Response (RECIST)
Secondary outcome measures
Progression-free Survival
Quality of Life Assessment
Toxicity Assessment
Side effects data
From 2013 Phase 3 trial • 4740 Patients • NCT0003846722%
Hot flushes NOS
18%
Arthralgia
16%
Fatigue
14%
Headache
13%
Insomnia
12%
Sweating increased
10%
Dizziness
10%
Hypertension NOS
9%
Back pain
9%
Nausea
6%
Depression
6%
Pain in limb
6%
Osteoarthritis NOS
6%
Weight increased
5%
Osteoporosis NOS
4%
Vaginal haemorrhage
1%
Abdominal pain
1%
Condition aggravated
100%
80%
60%
40%
20%
0%
Study treatment Arm
Exemestane
Tamoxifen
Trial Design
1Treatment groups
Experimental Treatment
Group I: Exemestane TherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exemestane
2003
Completed Phase 4
~7630
Find a Location
Who is running the clinical trial?
Masonic Cancer Center, University of MinnesotaLead Sponsor
276 Previous Clinical Trials
14,844 Total Patients Enrolled
Manish Patel, DOPrincipal InvestigatorUniversity of Minnesota Masonic Cancer Center
Share this study with friends
Copy Link
Messenger